Use of Aβ34 to assess Alzheimer's disease progression
AssigneeThe Royal Institution for the Advancement of Learning/Mcgill University
InventorsGerhard Multhaup, Adeola Shobo
Life of this patent
Estimating the term…
Abstract
It is provided an anti-Aβ34 antibody and its use for diagnosing Alzheimer's disease in a patient, comprising obtaining a sample from the patient, detecting the level of Aβ34 in the sample by contacting the sample with the anti-Aβ34 antibody and detecting binding between Aβ34 and the antibody, and diagnosing the patient with Alzheimer's disease when the presence of Aβ34 in the sample is detected, alone or in combination with detecting an amyloid deposition marker such as Aβ42 and determining the ratio of Aβ34/Aβ42.
Claims8
A method of diagnosing and treating Alzheimer's disease in a patient with mild cognitive impairment (MCI), the method comprising the following steps:
- (a) obtaining a sample from the patient wherein the sample is a cerebrospinal fluid (CSF) sample;
- (b) detecting a concentration of amyloid-β34 (Aβ34) in the sample of step (a) by contacting the sample with an anti-Aβ34 antibody and detecting binding between Aβ34 and the anti-Aβ34 antibody with an immunoassay;
- (c) detecting a concentration of amyloid-β42 (Aβ42) in the sample of step (a) by contacting the sample with an anti-Aβ42 antibody and detecting binding between Aβ42 and the anti-Aβ42 antibody with the immunoassay;
- (d) determining a concentration ratio of Aβ34/Aβ42 based on the concentration of Aβ34 detected in step (b) and the concentration of Aβ42 detected in step (c), wherein when the concentration ratio of Aβ34/Aβ42 is more than 0.245, the patient is diagnosed as having Alzheimer's disease;
- and
- (e) administering to the patient diagnosed as having Alzheimer's disease a treatment selected from the group consisting of an inhibitor of β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) and a synthetic 8-amino acid Aβ42-oligomer interacting Peptide (AIP).
Dependencies are inferred from the claim text.